About Pegfilgrastim
            
            Class: | Hematopoietic agent, Granulocyte colony-stimulating factor (G-CSF)  
Use: | Used to reduce the incidence of infection, as manifested by febrile neutropenia, in patients receiving myelosuppressive chemotherapy for malignancies.  
Adult dose: | 6 mg subcutaneously once per chemotherapy cycle, administered at least 24 hours after chemotherapy.  
Pediatric dose: | 6 mg subcutaneously once per chemotherapy cycle; dosing may vary based on specific clinical circumstances and should be determin
         
        
            
                
                
                    
                        Drug Class
                    
                    Hematopoietic agent, Granulocyte colony-stimulating factor (G-CSF)
                 
                
                
                    
                        Uses & Indications
                    
                    Used to reduce the incidence of infection, as manifested by febrile neutropenia, in patients receiving myelosuppressive chemotherapy for malignancies.
                 
                
                
                    
                        Storage Requirements
                    
                    Store in the refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze. Protect from light. Can be kept at room temperature (up to 25°C or 77°F) for up to 48 hours prior to administration.
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: Biocon Biologics Limited, India
                    
                    
                    Package Size
                    0.6 mL Prefilled Syringe
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 1927.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        6 mg subcutaneously once per chemotherapy cycle, administered at least 24 hours after chemotherapy.
                    
                    
                        Pediatric Dose
                    
                    
                        6 mg subcutaneously once per chemotherapy cycle; dosing may vary based on specific clinical circumstances and should be determined by a healthcare provider.
                    
                 
                
                
                    
                        Side Effects
                    
                    Bone pain, leukocytosis, splenic rupture, fatigue, nausea, vomiting, and injection site reactions.
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to pegfilgrastim or any component of the formulation; caution in patients with sickle cell disease or a history of splenic rupture.
         
        
        
            
                Important Warnings
            
            Risk of splenic rupture; monitor for signs of splenic enlargement or rupture. Use with caution in patients with pre-existing conditions that may predispose them to splenic rupture. Monitor for allergic reactions; discontinue use if severe reactions occur.
         
        
        
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.